(Reuters) - Gene therapy maker Bluebird bio said on Friday it would be taken private by Carlyle and SK Capital Partners, ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...

The Carlyle Group Inc. (NASDAQ:CG), a global investment firm with a market capitalization of $18.52 billion, has recently ...

BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...

The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...